NSCLC	Non-small cell lung cancer
BMs	Brain metastases
EGFR	Epidermal growth factor receptor
ALK	Anaplastic lymphoma kinase
PD-1	Programmed cell death-1
PD-L1	Programmed cell death ligand-1
CTLA-4	Cytotoxic T-lymphocyte antigen-4
ICI	Immune checkpoint inhibitor
mAb	Monoclonal antibody
RT	Radiotherapy
SRT	Stereotactic radiotherapy
WBRT	Whole-brain radiotherapy
HFRT	Hypofraction radiotherapy
CT	Chemotherapy, Computed tomography
AAT	Anti-angiogenic therapy
BBB	Blood-brain barrier
CSF	Cerebrospinal fluid
TME	Tumor microenvironment
TILs	Tumor-infiltrating lymphocytes
TAMs	Tumor-associated macrophages
Tregs	Regulatory T cells
MDSCs	Myeloid-derived suppressor cells
VEGF	Vascular endothelial growth factor
VEGFR	Vascular endothelial growth factor receptor
VCAM-1	Vascular cell adhesion molecule-1
ICAM-1	Intercellular adhesion molecule 1
INF	Interferon
CNS	Central never system
HR	Hazard ratio
CI	Confidence interval
CR	Complete response
PR	Partial response
ORR	Objective response rate
OS	Overall survival
PFS	Progression free survival
iPFS	Intracranial progression-free survival
iTTD	Intracranial time to development
AEs	Adverse events
trAEs	Treatment-related adverse events
QALY	Quality-adjusted life-year
FDA	Food and Drug Administration
lung-GPA	Lung-graded prognostic assessment
Ct-DNA	Circulating tumor DNA
CTCs	Circulating tumor cells
RECIST	Response Evaluation Criteria in Solid Tumors
RANO	Response Assessment in Neuro-oncology
RANO-HGG	RANO for High Grade Gliomas
RANO-BM	RANO for Brain Metastases
iRANO	immunotherapy RANO
mRECIST	modified RECIST
PET	Positron emission tomography
MR	Magnetic resonance